(HealthDay News) – A model that incorporates loss of heterozygosity data can accurately predict which patients with low-grade oral cancer are likely to progress to higher grades, according to a study published online Aug. 21 in Cancer Prevention Research.
Lewei Zhang, PhD, from the University of British Columbia in Vancouver, Canada, and colleagues analyzed samples from 296 patients with mild-to-moderate (low-grade) oral dysplasia to classify the risk of progression based on a previously proposed loss of heterozygosity model.
The researchers found that 5-year progression rates were 3.1% for patients classified as low risk, 16.3% for those classified as intermediate risk, and 63.1% for those classified as high risk. The risk of progression was 11.6-fold greater in patients at intermediate risk and 52.1-fold greater in patients at high risk, compared with those at low risk. The model was validated in an independent group of patients.
“In summary, this study provides the first validated molecular models for use in differentiating low-grade oral dysplasia at low risk for progression from those with greater risk, via the largest longitudinal study of low-grade oral premalignant lesions from a population-based patient group,” Zhang and colleagues conclude.